EGFR and head and neck cancer: For example, the EGFR signaling pathway is frequently abnormally active in head and neck cancer; its effects may be partly mediated by interfering with MOB1-dependent LATS1/2 activation in synergy with TAO kinase upregulation, collectively promoting YAP/TAZ activation (Ando et al., 2021).